GW Pharmaceuticals CEO: Pot-based epilepsy drug trial has taken a 'huge step'
British biotech GW Pharmaceuticals took one step closer to having its key childhood epilepsy drug Epidiolex approved on Monday, when it announced promising phase 3 clinical trial results. Shares of the stock soared more than 17 percent in response.
In an interview with Jim Cramer on Monday, GW Pharma CEO Justin Gover said that the children participating in the trial had previously tried 10 other anti-epileptic drugs. Despite the medication, they still had three seizures a day, approximately 90 a month.
"The impact that we have had that we have shown today is a hugely important potential breakthrough in the treatment of the condition called Lennox-Gastaut syndrome," Gover told the host of CNBC's "Mad Money. "A file photo of marijuana plants Gina Ferazzi | Los Angeles Times | Getty Images
Epidiolex is an orphan drug that is pharmaceutical cannabidiol, not medical marijuana. The drug helps treat various types of pediatric epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome. GW Pharma's study revealed that patients taking 20 mg of Epidiolex had a medium reduction in monthly seizures of 42 percent versus a 17 percent reduction for those on placebo.
- Cannabis-Based Epilepsy Drug on Verge of Approval by the FDA | CannaSOScannasos.com
- FDA Approves Cannabis-Based Epilepsy Medicationhightimes.comJune 25, 2018
- GW Pharmaceuticals doubles in value after cannabis drug success in epilepsy trialwww.theguardian.comMarch 14, 2016
- GW Pharmaceuticals is Uncle Sam’s Version of Legal Weed | Cannabis Nowcannabisnow.comMarch 18, 2016